MedTech Consolidation: Dassault Systèmes Acquires ArisGlobal for $1.8B for AI Platform

Industrial software is aggressively merging with biological data analysis algorithms. On July 23, 2026, European developer Dassault Systèmes officially confirmed the acquisition of ArisGlobal for $1.8 billion, while simultaneously confirming its full-year revenue outlook.

The deal aims to build an AI-native platform for the pharmaceutical sector and Life Sciences. ArisGlobal specializes in clinical trial automation and drug compliance control. Integrating these systems into Dassault Systèmes’ simulation engines will allow pharma giants to model the effects of new molecules on digital organ twins before real-world testing even begins. This is a prime example of traditional software monopolists solidifying their B2B positions by buying up highly specialized AI assets to address specific industry pain points.

Source: Dassault Systèmes / ArisGlobal / Reuters